Reach Us +44 1223 790975


Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Autologous Neural Cell Therapy Reverses A Dementia Syndrome In Older Pet Dogs | 96414
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

6th World Congress on Epilepsy and Brain Disorders

Valencia, Spain

5th World Brain Congress

Rome, Italy
Google Scholar citation report
Citations : 2590

Journal of Alzheimers Disease & Parkinsonism received 2590 citations as per Google Scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Autologous neural cell therapy reverses a dementia syndrome in older pet dogs

12th World Congress on Advances and Innovations in Dementia

Thomas Duncan

University of Sydney, Australia

ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460-C5-048

Dementia currently affects 50 million individuals worldwide, with projections of 130 million by the year 2050. Due to limited progress in medical management dementia remains an incurable and fatal disorder. The underlying clinicpathologic issue in early Alzheimer???s dementia is mass neuronal loss in the hippocampus. Repopulation by exogenous neural precursors is a promising therapeutic strategy but has yet to reach clinical trial. One of the major challenges has been poor translational fidelity between rodents and humans. We have therefore focused on Canine Cognitive Dysfunction (CCD), a neurodegenerative disorder in older pet dogs with many parallels to human Alzheimer???s and dementia. Dogs with CCD display amnesia, spatial disorientation and agitation and express neurodegeneration alongside Alzheimer pathology. To date, we have produced >50 genetically non-modified neural precursor cell lines from adult canine skin, termed SKNs. These are highly homogenous in culture, rate-limited by virtue of low number of maximal cell doublings and differentiate almost exclusively into neurons, endogenously up-regulating neuronal specification genes. We show that canine SKN transplantation into the aged rodent hippocampus is safe and leads to widespread neuronal engraftment. Donor cells become electro-physiologically active and integrate synaptically into host neuronal circuitry. Moreover, we observe rescue of hippocampal-dependent place recognition memory deficits, with exploration ratio restored to levels equivalent with young rats. Accordingly, we are now assessing the safety and efficacy of our SKN therapy in a world-first therapeutic trial to treat dementia in a higher-order animal model. We can report that 18-months following MRI-guided intra-hippocampal injection of autogenic SKNs, two consecutive patients demonstrate stable and clinically meaningful improvement in CCD signs, such that they are functionally cured. These results are paralleled by dramatic improvements on objective spatial memory testing. These exciting early trial results indicate that SKN therapy can, in-principle reverse a naturalistic dementia-like syndrome.

Thomas Duncan is a Postdoctoral Researcher at the University of Sydney, Australia. His background is in histology, cell biology and regenerative medicine. At the University of Sydney, he manages Australia’s first Canine Brain Bank and leads research into the neuropathology of canine dementia and the development of an autologous cell therapy for human Alzheimer’s disease. He is a Lecturer at the University of Sydney of Neuroscience, Regenerative Medicine and Human Anatomy and Histology.

E-mail: [email protected]